ResMed Inc. (NYSE:RMD) Shares Bought by Captrust Financial Advisors

Captrust Financial Advisors increased its holdings in ResMed Inc. (NYSE:RMD) by 901.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,537 shares of the medical equipment provider’s stock after purchasing an additional 43,689 shares during the period. Captrust Financial Advisors’ holdings in ResMed were worth $11,849,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Versor Investments LP raised its stake in ResMed by 327.3% during the second quarter. Versor Investments LP now owns 4,700 shares of the medical equipment provider’s stock worth $900,000 after purchasing an additional 3,600 shares during the period. Assenagon Asset Management S.A. boosted its holdings in ResMed by 245.2% in the second quarter. Assenagon Asset Management S.A. now owns 33,507 shares of the medical equipment provider’s stock valued at $6,414,000 after acquiring an additional 23,801 shares during the last quarter. Addenda Capital Inc. grew its position in ResMed by 17.4% during the second quarter. Addenda Capital Inc. now owns 58,986 shares of the medical equipment provider’s stock valued at $11,291,000 after acquiring an additional 8,747 shares during the period. Retireful LLC acquired a new stake in ResMed during the third quarter worth about $742,000. Finally, Asset Management One Co. Ltd. raised its holdings in shares of ResMed by 5.1% in the 3rd quarter. Asset Management One Co. Ltd. now owns 58,860 shares of the medical equipment provider’s stock worth $14,369,000 after purchasing an additional 2,878 shares during the period. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RMD has been the subject of a number of research reports. Robert W. Baird boosted their target price on ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Royal Bank of Canada increased their price objective on shares of ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research report on Friday, October 25th. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Baird R W upgraded ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, KeyCorp boosted their price objective on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $225.70.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $239.90, for a total transaction of $479,800.00. Following the completion of the sale, the director now owns 87,204 shares in the company, valued at $20,920,239.60. The trade was a 2.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Witte Jan De sold 796 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the transaction, the director now owns 6,723 shares in the company, valued at approximately $1,672,749.63. The trade was a 10.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,334 shares of company stock worth $16,379,713 over the last quarter. 0.71% of the stock is owned by corporate insiders.

ResMed Stock Performance

Shares of RMD opened at $249.02 on Monday. The firm has a market cap of $36.56 billion, a price-to-earnings ratio of 32.98, a PEG ratio of 1.81 and a beta of 0.69. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average is $242.24 and its two-hundred day moving average is $225.70. ResMed Inc. has a 52-week low of $156.39 and a 52-week high of $260.49.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.17. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.64 EPS. Analysts forecast that ResMed Inc. will post 9.28 EPS for the current fiscal year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.85%. The ex-dividend date is Thursday, November 7th. ResMed’s payout ratio is currently 28.08%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.